Bioprojet

Societe Civile Bioprojet

Institut National De La Sante Et De La Recherche Medicale

Other

Bioproject

Societe Civile Bioproject

Adir Et Compagnie

Sun Pharma Advanced Research Company Limited

Université De Caen

Bioprojet Pharma

Societe Civile Brioprojet

Universite De Caen - Esplanade De La Faix

Camille Georges Wermuth

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Denis Danvy

Xavier Ligneau

Marc Capet

Pierre Duhamel

Lucette Duhamel

Jean-Michel Arrang

Philippe Robert

Claude Gros

Monique Garbarg

Jean-Christophe Plaquevent

Thierry Monteil

Nicolas Levoin

Walter Schunack

Isabelle Berrebi-Bertrand

Holger Stark

Thierry Calmels

Olivier Labeeuw

Charon R Ganellin

Ralph Lipp

Pierre Sokoloff

Stéphane Krief

Xavier Billot

Bruno Giros

Nadine Noel

Katja Purand

Bernard P Roques

Camille-Georges Wermuth

André Mann

Fabrice Garrido

Sigurd Elz

Fabien Leurquin

Wasyl Tertiuk

Abdellatif Fkyerat

Olivier Chamard

Serge Piettre

Mark Millan

Jean-Louis Peglion

Rajamannar Thennati

Antonio Guglietta

Bertrand Goument

Manuel M Raga

Joel Vian

Olivia Poupardin-Olivier

Juan Sallares

Jayraj Dilipbhai Aradhye

Bhavesh Mohanbhai Panchal

Biswajit Samanta

Ranjan Kumar Pal

Marta Guerrero

Helene Greciet

Lihua Zhao

Charon Ganellin

Muthukumaran Natarajan Pillai

Isabelle Bertrand

Max-Fernand Robba

Jean-Charles M Lancelot

Marie-Pascale Martres

Christophe Lusson

Froylan Vargas

Bertrand Leblond

Marc Maury

Valerie Audinot

David Perrin

Sandeep Pankajbhai Pathak

Japan Nitinkumar Desai

Didier Rognan

Paul Beaumont Bishop

Ramesh B Bambal

Andrew N J Moore

Suzanne Chan

Yondjun Chen

Samad Sanjeeda

Rose Christiania

Agnes Quemener

Walter G Schunack

Annette Huls

Reidemeister Sybille

Athmani Salah

Laurent François Gérard Landais

Nadia Pelloux-Leon

Charon Robbin Ganellin

Wasyl Tertiux

Sadek Bassem

Michael C O Krause

Jean-Stëphane Julien

Nadine Noel-Lefebvre

Dijixa Chandubhai Rana

Monigue Garborg

Giros Bruno

Kaushik Dhanjubhai Prajapati

Val Erie Audinot

Marcel Morvan

Jeanne-Marie Lecounte

Walter G Schunacx

Hulger Stark

G&eacute;rard Coquerel

Marie-No&euml;lle Petit

Christiane Rose

The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.

Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands

Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.

The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.

Therapeutical use of H3-ligands

The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.

Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same

The present invention concerns a novel combination of adrenalin with an antidepressant and its use as a pharmaceutical composition for the treatment of shocks. A method is also provided for treating a subject in need thereof by administering the combination of adrenaline with an antidepressant. The pharmaceutical composition is to be administered by injection.

Combination of adrenalin with an antidepressant for use in the treatment of shocks

The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.

Form of administration of enkephalinase inhibitor

The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation. 

Piperidinyl monocarboxylic acids as S1P1 receptor agonists

The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands

The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.

(Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications

Benzazole derivatives as histamine H4 receptor ligands

The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.

Dicarboxylic acid derivatives as S1P1 receptor agonists

The present patent application concerns new ligands of the H4-receptor of formula (I), their process of preparation and their therapeutic use. 

The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent. 

[object Object]

The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H-receptors of histamine.

A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2&#x3b8;) at 11.2&#xb0;, 19.9&#xb0;, 20.7&#xb0; and 34.1&#xb0;&#xb1;0.2&#xb0; is administered to a patient in need thereof.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine

Growing community of inventors

Paris, France

Jean-Charles Schwartz